195 related articles for article (PubMed ID: 10851069)
41. Core binding factor cannot synergistically activate the myeloperoxidase proximal enhancer in immature myeloid cells without c-Myb.
Britos-Bray M; Friedman AD
Mol Cell Biol; 1997 Sep; 17(9):5127-35. PubMed ID: 9271390
[TBL] [Abstract][Full Text] [Related]
42. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.
Okuda T; van Deursen J; Hiebert SW; Grosveld G; Downing JR
Cell; 1996 Jan; 84(2):321-30. PubMed ID: 8565077
[TBL] [Abstract][Full Text] [Related]
43. The role of the AML1 transcription factor in leukemogenesis.
Lorsbach RB; Downing JR
Int J Hematol; 2001 Oct; 74(3):258-65. PubMed ID: 11721960
[TBL] [Abstract][Full Text] [Related]
44. Revealing the role of TEL/AML1 for leukemic cell survival by RNAi-mediated silencing.
Zaliova M; Madzo J; Cario G; Trka J
Leukemia; 2011 Feb; 25(2):313-20. PubMed ID: 21109770
[TBL] [Abstract][Full Text] [Related]
45. Overexpression of core-binding factor alpha (CBF alpha) reverses cellular transformation by the CBF beta-smooth muscle myosin heavy chain chimeric oncoprotein.
Hajra A; Liu PP; Speck NA; Collins FS
Mol Cell Biol; 1995 Sep; 15(9):4980-9. PubMed ID: 7651416
[TBL] [Abstract][Full Text] [Related]
46. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation.
Burel SA; Harakawa N; Zhou L; Pabst T; Tenen DG; Zhang DE
Mol Cell Biol; 2001 Aug; 21(16):5577-90. PubMed ID: 11463839
[TBL] [Abstract][Full Text] [Related]
47. Runx2 induces acute myeloid leukemia in cooperation with Cbfbeta-SMMHC in mice.
Kuo YH; Zaidi SK; Gornostaeva S; Komori T; Stein GS; Castilla LH
Blood; 2009 Apr; 113(14):3323-32. PubMed ID: 19179305
[TBL] [Abstract][Full Text] [Related]
48. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.
Durst KL; Lutterbach B; Kummalue T; Friedman AD; Hiebert SW
Mol Cell Biol; 2003 Jan; 23(2):607-19. PubMed ID: 12509458
[TBL] [Abstract][Full Text] [Related]
49. Gfi1 and Gfi1b: key regulators of hematopoiesis.
van der Meer LT; Jansen JH; van der Reijden BA
Leukemia; 2010 Nov; 24(11):1834-43. PubMed ID: 20861919
[TBL] [Abstract][Full Text] [Related]
50. The core binding factor CBF negatively regulates skeletal muscle terminal differentiation.
Philipot O; Joliot V; Ait-Mohamed O; Pellentz C; Robin P; Fritsch L; Ait-Si-Ali S
PLoS One; 2010 Feb; 5(2):e9425. PubMed ID: 20195544
[TBL] [Abstract][Full Text] [Related]
51. AML1/CBFbeta transcription complex: its role in normal hematopoiesis and leukemia.
Downing JR
Leukemia; 2001 Apr; 15(4):664-5. PubMed ID: 11368373
[No Abstract] [Full Text] [Related]
52. CBFbeta is critical for AML1-ETO and TEL-AML1 activity.
Roudaia L; Cheney MD; Manuylova E; Chen W; Morrow M; Park S; Lee CT; Kaur P; Williams O; Bushweller JH; Speck NA
Blood; 2009 Mar; 113(13):3070-9. PubMed ID: 19179469
[TBL] [Abstract][Full Text] [Related]
53. RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.
Zhen T; Cao Y; Ren G; Zhao L; Hyde RK; Lopez G; Feng D; Alemu L; Zhao K; Liu PP
Blood; 2020 Nov; 136(21):2373-2385. PubMed ID: 32929473
[TBL] [Abstract][Full Text] [Related]
54. The transcriptionally active form of AML1 is required for hematopoietic rescue of the AML1-deficient embryonic para-aortic splanchnopleural (P-Sp) region.
Goyama S; Yamaguchi Y; Imai Y; Kawazu M; Nakagawa M; Asai T; Kumano K; Mitani K; Ogawa S; Chiba S; Kurokawa M; Hirai H
Blood; 2004 Dec; 104(12):3558-64. PubMed ID: 15271791
[TBL] [Abstract][Full Text] [Related]
55. [The role of cycline dependent kinase 4 in the malignant transformation induced by silica].
Yan KX; Liu BC; Shi XL; Zhang XM; You BR; Xu M; Kang N
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2004 Oct; 22(5):331-5. PubMed ID: 15555303
[TBL] [Abstract][Full Text] [Related]
56. VWRPY motif-dependent and -independent roles of AML1/Runx1 transcription factor in murine hematopoietic development.
Nishimura M; Fukushima-Nakase Y; Fujita Y; Nakao M; Toda S; Kitamura N; Abe T; Okuda T
Blood; 2004 Jan; 103(2):562-70. PubMed ID: 14504086
[TBL] [Abstract][Full Text] [Related]
57. TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL.
Morrow M; Samanta A; Kioussis D; Brady HJ; Williams O
Oncogene; 2007 Jun; 26(30):4404-14. PubMed ID: 17237815
[TBL] [Abstract][Full Text] [Related]
58. Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes.
Kwok C; Zeisig BB; Qiu J; Dong S; So CW
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2853-8. PubMed ID: 19202074
[TBL] [Abstract][Full Text] [Related]
59. PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells.
Nuchprayoon I; Meyers S; Scott LM; Suzow J; Hiebert S; Friedman AD
Mol Cell Biol; 1994 Aug; 14(8):5558-68. PubMed ID: 8035830
[TBL] [Abstract][Full Text] [Related]
60. Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation.
Kanno Y; Kanno T; Sakakura C; Bae SC; Ito Y
Mol Cell Biol; 1998 Jul; 18(7):4252-61. PubMed ID: 9632809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
